Skip to main content

Month: February 2026

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027 Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026 FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; expected to fund operations into the second half of 2027CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial...

Continue reading

Collegium Reports Fourth Quarter and Full-Year 2025 Financial Results

– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents, and Marketable Securities of $386.7 Million – – Reaffirmed Full-Year 2026 Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter and full year ended December...

Continue reading

Colliers named to IAOP’s Global 100 for 20th consecutive year

Two decades of global service excellence underscore Colliers’ commitment to client success TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Colliers (NASDAQ, TSX: CIGI), a leading diversified professional services and investment management company, has been named to the 2026 Global 100 list produced by IAOP® in the Leader category for large, established global firms. This marks the 20th consecutive year that Colliers has been recognized for global service excellence. IAOP’s annual list recognizes the world’s top outsourcing service providers and advisors based on rigorous evaluation criteria, including customer references, awards and certifications, programs for innovation, and corporate social responsibility. The IAOP Global 100 serves as a trusted resource for organizations seeking high-performing partners across a broad range of outsourcing...

Continue reading

Diana Shipping Inc. Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2025; and Declares Cash Dividend of $0.01 Per Common Share for the Fourth Quarter 2025

ATHENS, Greece, Feb. 26, 2026 (GLOBE NEWSWIRE) — Diana Shipping Inc. (NYSE: DSX), (the “Company”), a global shipping company specializing in the ownership and bareboat charter-in of dry bulk vessels, today reported net income of $3.1 million and net income attributable to common stockholders of $1.7 million for the fourth quarter of 2025. This compares to net income of $9.7 million and net income attributable to common stockholders of $8.3 million for the fourth quarter of 2024. Earnings per share for the fourth quarter of 2025 were $0.02 basic and diluted, compared to $0.07 basic and $0.02 diluted in the same quarter of 2024. Time charter revenues were $52.1 million for the fourth quarter of 2025, compared to $57.1 million for the same quarter of 2024. The decrease was primarily attributable to the sale of two vessels in 2025...

Continue reading

Conavi Medical Reports Fiscal First Quarter 2026 Results and Operational Highlights

– Successfully Closes $12M Public Offering, Strengthens Balance Sheet and Supports Anticipated U.S. Launch– Recent Peer-Reviewed Publication Demonstrates Advantages of Hybrid IVUS-OCT Imaging TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Conavi Medical Corp. (TSXV: CNVI) (OTCQB: CNVIF) (“Conavi” or the “Company”), a medical device company focused on designing, manufacturing, and marketing imaging technologies to guide minimally invasive cardiovascular procedures, today reported financial results and provided an operational update for the fiscal quarter ended December 31, 2025 (Fiscal Q1 2026). “Conavi is approaching a key inflection point with anticipated U.S. FDA 510(k) clearance of our next-generation Novasight Hybrid™ system in the first half of 2026,” said Thomas Looby, President and Chief Executive Officer of...

Continue reading

Anika Reports Fourth Quarter and Full Year 2025 Financial Results

Met 2025 revenue and exceeded revised adjusted EBITDA; reaffirms 2026 revenue and sets adjusted EBITDA target Commercial Channel grew 22% and 15% for Q4 and full year, respectively Generated $11.2 million operating cash flow and $4.4 million in free cash flow for the full year FDA response for Hyalofast® PMA received in January 2026, Anika developing responses for submission BEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early‑intervention orthopedics, today announced financial results for the fourth quarter and full year ended December 31, 2025. Anika reported fourth quarter revenue of $30.6 million, flat compared to the fourth quarter of 2024. Gross margin expanded to 63%, driven...

Continue reading

Calian and ADGA Group Sign Collaborative Agreement to Advance Next-Generation Land Training and Simulation for the Canadian Army

Collaboration will deliver collective training designed and delivered to meet today’s modern battlefield and Canada’s defence modernization priorities OTTAWA, Ontario, Feb. 26, 2026 (GLOBE NEWSWIRE) — Calian Group Ltd. (TSX: CGY) and ADGA Group Consultants Inc. today announced a three-year collaboration agreement to explore the development of next-generation integrated land training and simulation for the Canadian Army. Under the terms of the agreement, Calian and ADGA have defined a partner framework that aligns their complementary expertise and technologies to meet the accelerating operational demands of the Canadian Army and the realities of modern warfare. “In an era of accelerating, multi-domain threats, the readiness of the Canadian Army is non-negotiable. World-class, modern training that replicates operational complexity...

Continue reading

Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025 GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025 Adjusted fully diluted earnings per share of $1.67 and $6.08 for the fourth quarter and full year 2025 Repurchased $100 million of shares of common stock in the fourth quarter pursuant to the previously announced stock repurchase plan that was approved by the Board in July 2025 Company announced today that it is sharpening its strategic focus to innovative radiodiagnostics and pursuing value‑maximizing alternatives for radiotherapeutic assets to support long-term growth Company provides full year 2026 revenue and adjusted fully diluted earnings per share guidanceBEDFORD, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc....

Continue reading

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

– Positive Interim Results of Phase 1a Single (SAD) and Multiple Ascending Dose (MAD) Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Support Rapid Clinical Advancement; Complete Top Line Results Expected in the Second Quarter of 2026 – – Phase 1b Proof-of-Concept Trials of ATI-052 in Atopic Dermatitis (AD) and Asthma Underway; Top Line Results from Both Trials Anticipated in the Second Half of 2026 – – Investigational New Drug (IND) Application for Lead ITK Inhibitor Candidate ATI-9494 Expected in the SecondHalf of 2026 – – ATI-2138, Aclaris’ Investigational Inhibitor of ITK and JAK3, Demonstrated Potential Best-in-Class Hair Regrowth in Murine Alopecia Model – WAYNE, Pa., Feb. 26, 2026 (GLOBE NEWSWIRE) — Aclaris Therapeutics, Inc. (NASDAQ: ACRS),...

Continue reading

Eos Energy Enterprises Reports Fourth Quarter and Full Year 2025 Financial Results; Delivers More than 7x Year-Over-Year Revenue Growth and Initiates 2026 Revenue Guidance

$58.0 million in record quarterly revenue with Q4 exceeding the first three 2025 quarters combined  Secured over $240 million with nearly 1.1 GWh of new orders in Q4 from eight customers spanning U.S. and international markets, highlighting diversified market demand Successfully executed a $600 million senior convertible notes issuance and registered direct common stock offering, ending the year with a record cash balance of $624.6 million Current liquidity and operational funding plan support ongoing operations and substantial doubt no longer exists about Company’s ability to continue as a going concern Launched Indensity™, a next-generation architecture built with Spatial Intelligence that targets up to 1 GWh per acre while delivering industry-leading flexibility and safety Initiates 2026 revenue guidance of $300 million to...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.